Nalorphine
![ADVANCED RELEASE EMCDDA Technical Report on the New Psychoactive Substance N,N- Diethyl-2-[[4-(1-Methylethoxy)Phenyl]Methyl]-5-N](http://data.docslib.org/img/264x/262991676ce9525cf43f301c19c480ef.webp)
Top View
- Agonist-Antagonist Opioids: Theory and Clinical Practice Carl Rosow MD
- Controlled Substance Conversion Factors
- Properties of Opiate-Receptor Binding in Rat Brain (Naloxone/Opiate Antagonist)
- National Clearinghouse for Drug Abuse Information Selected Reference Series, Series 4, No
- Development of Diphenethylamines As Selective Kappa Opioid Receptor Ligands and Their Pharmacological Activities
- United States Patent (19) 11 Patent Number: 4,692,451 Dodman Et Al
- Narcotics Dangerous Drugs
- Natural Products As a Source for Novel Analgesic Compounds
- Chemogenomics Knowledgebase and Systems Pharmacology for Hallucinogen Target Identification Salvinorin a As a Case Study
- Food and Drug Administration, HHS § 862.3650
- Tolerance, Antagonism and the Relation Between D-Lysergic Acid Diethylamide and Mescaline" (1958)
- Electrophysiological Interactions of Isomers of Cyclazocine with the Phencyclidine Antagonist Metaphit in Rat Cerebellar Purkinje Neurons
- Strategies for Developing Kappa Opioid Receptor Agonists for the Treatment of Pain with Fewer Side-Effects
- FDA Advisory Committee on the Most Appropriate Dose Or Doses of Naloxone to Reverse the Effects of Life-Threatening Opioid Overdose in the Community Settings
- Research Issues 26
- Pentazocine, Cyclazocine, and Nalorphine As Discriminative Stimuli
- United States Patent (19) 11 Patent Number: 5,866,164 Kuczynski Et Al
- Ed Domino's Early Studies of Psychoactive Drugs